Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, at a CAGR of 19.4%.

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Biogen Pharmachem Industries Ltd share price was up by 0.98% from the previous closing price of ₹1.02. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Kane Realty sells prime Downtown Raleigh asset in major deal © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion ...